Link Pharma Chem

Why is Link Pharma Chem Ltd falling/rising?

As of 24-Aug, Link Pharma Chem Ltd's stock price is rising to 28.00, with a 1.82% increase today and a total return of 6.87% over the last two days. However, despite recent gains, the stock has a year-to-date decline of 9.09% and shows signs of reduced investor participation.

As of 24-Aug, Link Pharma Chem Ltd's stock price is rising, currently at 28.00, with a change of 0.5 (1.82%) upwards. The stock has shown a notable performance today, outperforming its sector by 1.83%. It has been on a consecutive gain for the last two days, accumulating a total return of 6.87% during this period. Additionally, the stock has experienced a positive return of 5.54% over the past week, contrasting with a slight decline of 0.46% in the Sensex during the same timeframe.<BR><BR>Despite the recent gains, it is important to note that the stock has faced challenges over longer periods, with a year-to-date decline of 9.09% and a significant drop of 21.98% over the past year. However, the current upward movement may be attributed to recent trading activity, as the stock has been trading above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short-term positive trend. <BR><BR>Nevertheless, there are signs of falling investor participation, as evidenced by a significant drop in delivery volume, which decreased by 58.98% against the 5-day average. This could suggest that while the stock is currently rising, there may be underlying concerns regarding sustained interest from investors. Overall, the recent price increase is primarily driven by short-term gains and positive performance relative to the sector.

Which are the latest news on Link Pharma Chem?

Who are in the management team of Link Pharma Chem?

The management team of Link Pharma Chem consists of S G Thakur (Chairman & Wholetime Director), Rishikesh S. Thakur (Managing Director), and independent directors S B Dhatrak, Devang U Shah, and Rachna Ghai.

The management team of Link Pharma Chem includes the following individuals:<BR><BR>1. S G Thakur - Chairman & Wholetime Director<BR>2. Rishikesh S. Thakur - Managing Director<BR>3. S B Dhatrak - Independent Director<BR>4. Devang U Shah - Independent Director<BR>5. Rachna Ghai - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Link Pharma Chem do?

Link Pharma Chem Ltd is a mid-size chemical manufacturing company established in 1986, specializing in commodity chemicals with a current production capacity of 2,100 tons per annum. As of June 2026, it reported net sales of 9 Cr and a market cap of INR 12 Cr.

Overview:<BR>Link Pharma Chem Ltd is a mid-size leading chemical manufacturing company operating in the commodity chemicals industry, categorized as a micro-cap.<BR><BR>History:<BR>Incorporated in 1986, Link Pharma Chem has undergone several capacity expansions, increasing its production from 300 tons per annum to 2100 tons per annum by 1994. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 9 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 486,181,658,489,704,256.00 <BR>Industry P/E: 13 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.52 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.93 <BR><BR>Contact Details:<BR>Address: 162, GIDC Ind Estate Nandesari Vadodara Gujarat : 391340 <BR>Tel: 91-0265-3065000/2840448/3093931 <BR>Email: linkpharmacs@gmail.com <BR>Website: http://www.linkpharmachem.co.in

Who are the peers of the Link Pharma Chem?

Link Pharma Chem's peers include Square Four Pro., Vivid Global, Advance Petroch., Omkar Pharmachem, Kobo Biotech, Emmessar Biotech, Kuwer Industries, Sreechem Resins, and Lime Chemicals. Link Pharma Chem has below average management risk and growth, with a capital structure rated below average, while Kobo Biotech leads in 1-year returns at 111.76%, compared to Link Pharma Chem's -25.10%.

Peers: The peers of Link Pharma Chem are Square Four Pro., Vivid Global, Advance Petroch., Omkar Pharmachem, Kobo Biotech, Emmessar Biotech, Kuwer Industries, Sreechem Resins, and Lime Chemicals.<BR><BR>Quality Snapshot: Below Average management risk is observed at Link Pharma Chem, Vivid Global, Kuwer Industries, Emmessar Biotech, and Lime Chemicals, while Average management risk is found at Advance Petroch. and Emmessar Biotech. The peers with Below Average growth include Link Pharma Chem, Vivid Global, Emmessar Biotech, Kuwer Industries, and Lime Chemicals, while Advance Petroch. shows Good growth. Capital Structure ratings reveal that Good capital structure is present at Vivid Global, while Below Average capital structure is noted for Link Pharma Chem, Advance Petroch., Emmessar Biotech, Kuwer Industries, and Lime Chemicals.<BR><BR>Return Snapshot: Kobo Biotech has the highest 1-year return at 111.76%, while Link Pharma Chem has the lowest at -25.10%. This indicates that Link Pharma Chem's return is significantly lower than that of Kobo Biotech. Additionally, Sreechem Resins and Omkar Pharmachem have negative six-month returns.

How big is Link Pharma Chem?

As of 14th August, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr and reported Net Sales of 28.38 Cr with a net profit loss of 0.00 Cr over the latest four quarters. Shareholder's Funds are 12.79 Cr and Total Assets are valued at 24.81 Cr as of March 2026.

As of 14th August, Link Pharma Chem Ltd has a market capitalization of 12.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Link Pharma Chem reported Net Sales of 28.38 Cr. The Net Profit for the same period was recorded as a loss of 0.00 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's Funds stood at 12.79 Cr, while Total Assets were valued at 24.81 Cr.

Are Link Pharma Chem Ltd latest results good or bad?

Link Pharma Chem Ltd's latest results show a 33.08% revenue growth to ₹8.77 crores, indicating short-term recovery; however, net profit declined by 20% and operating margins fell, highlighting ongoing profitability challenges and weak long-term fundamentals. Investors should exercise caution due to these structural issues.

Link Pharma Chem Ltd's latest results present a mixed picture. On one hand, the company achieved a significant sequential revenue growth of 33.08%, reaching ₹8.77 crores in Q1 FY27, which is a positive indicator of short-term recovery. However, this growth comes with notable concerns.<BR><BR>Despite the revenue increase, the net profit for the quarter was ₹0.32 crores, which is a decline of 20% compared to the same quarter last year. Furthermore, the operating margin has decreased to 5.13% from 8.19% year-on-year, indicating that the company is struggling with cost management and profitability. The profit margins, both operating and PAT, have deteriorated, reflecting ongoing challenges in the competitive commodity chemicals sector.<BR><BR>Additionally, the long-term fundamentals of the company appear weak, with a five-year sales CAGR of -4.66% and EBIT CAGR of -26.52%. This suggests that the company has faced sustained contraction in revenue and operating profits over the years.<BR><BR>Overall, while there are signs of a short-term recovery in revenue, the underlying issues with profitability and long-term growth prospects suggest that the results are more concerning than encouraging. Investors should be cautious given the structural challenges the company faces.

Should I buy, sell or hold Link Pharma Chem Ltd?

When is the next results date for Link Pharma Chem Ltd?

Link Pharma Chem Ltd will announce its results on 05 August 2026.

Link Pharma Chem Ltd is scheduled to declare its results on 05 August 2026.

How has been the historical performance of Link Pharma Chem?

Link Pharma Chem has experienced a significant decline in net sales and profitability, with losses reported in the most recent fiscal year. Net sales dropped from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, and the company reported a profit after tax loss of -1.03 Cr in March 2025.

Answer:<BR>The historical performance of Link Pharma Chem shows a declining trend in net sales and profitability over the past few years, culminating in losses in the most recent fiscal year.<BR><BR>Breakdown:<BR>Link Pharma Chem's net sales have decreased from 53.56 Cr in March 2022 to 25.43 Cr in March 2025, reflecting a significant decline. The total operating income followed a similar trend, dropping from 53.56 Cr in March 2022 to 25.43 Cr in March 2025. The company's total expenditure also decreased, but not as sharply, leading to operating profits that turned negative in March 2024 and remained low at 0.31 Cr in March 2025. Profit before tax has been negative since March 2024, with a loss of 1.40 Cr reported in March 2025. Consequently, the profit after tax also showed losses, amounting to -1.03 Cr in March 2025. The company's total assets decreased from 32.46 Cr in March 2023 to 23.06 Cr in March 2025, while total liabilities also fell from 25.95 Cr to 23.06 Cr in the same period. Cash flow from operating activities was positive at 2.00 Cr in March 2025, but the overall cash position remained stagnant, with no cash inflow or outflow reported. Overall, Link Pharma Chem has faced significant challenges, leading to declining revenues and profitability over the years.

Is Link Pharma Chem overvalued or undervalued?

As of May 28, 2025, Link Pharma Chem is considered risky and overvalued with a negative PE ratio of -15.17 and a year-to-date return of -12.29%, significantly underperforming compared to its peers like Godrej Industries and the Sensex.

As of 28 May 2025, the valuation grade for Link Pharma Chem has moved from very attractive to risky. The company is currently assessed as overvalued, given its negative PE ratio of -15.17, an EV to EBITDA of 22.01, and a ROE of -7.51%. These ratios indicate significant financial distress and a lack of profitability, which is concerning for potential investors.<BR><BR>In comparison to its peers, Link Pharma Chem's valuation metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a more favorable market position. Additionally, Solar Industries is deemed very expensive with a PE ratio of 123.77, highlighting the disparity in valuation within the sector. Despite a recent uptick in stock price, Link Pharma Chem's year-to-date return of -12.29% significantly underperforms the Sensex's 5.66%, reinforcing the notion of its overvaluation.

What is the technical trend for Link Pharma Chem?

As of June 5, 2025, Link Pharma Chem's trend has shifted to bearish, supported by bearish indicators from moving averages and Bollinger Bands, despite some mixed signals from the MACD and KST.

As of 5 June 2025, the technical trend for Link Pharma Chem has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD is mildly bullish, but the monthly MACD indicates a bearish trend. Both the weekly and monthly Bollinger Bands confirm a bearish outlook. Daily moving averages are also bearish, reinforcing the negative sentiment. The KST shows a mildly bullish signal on the weekly chart, but is bearish on the monthly, indicating mixed signals. Overall, the lack of clear trends in Dow Theory further supports a bearish perspective.

Who are the top shareholders of the Link Pharma Chem?

The top shareholders of Link Pharma Chem include Rishikesh Satishbhai Thakur with 18.95%, followed by Gurudev Marketing Pvt. Ltd. at 5.76%, and individual investors holding 37.17%. There are no pledged promoter holdings, minimal mutual fund involvement, and no foreign institutional investors.

The top shareholders of Link Pharma Chem include the promoters, with Rishikesh Satishbhai Thakur holding the largest share at 18.95%. The company has no pledged promoter holdings. In terms of public shareholders, Gurudev Marketing Pvt. Ltd. is the highest public shareholder with a stake of 5.76%. Additionally, individual investors collectively hold 37.17% of the shares. Mutual funds have a minimal presence, with only one scheme holding 0.02%, and there are currently no foreign institutional investors (FIIs) involved.

Has Link Pharma Chem declared dividend?

No Dividend History Available